Pharmacokinetics of Telavancin in Normal and Obese Subjects

Trial Profile

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Telavancin (Primary)
  • Indications Bacteraemia; Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Jan 2018 Results published in the Antimicrobial Agents and Chemotherapy
    • 25 Apr 2017 Results assessing pharmacokinetics of fixed dose telavancin presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 According to a Theravance Biopharma media release,data from this trial was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top